

Massimiliano Castellazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/744228/publications.pdf>

Version: 2024-02-01

75
papers

2,273
citations

172386

29
h-index

243529

44
g-index

77
all docs

77
docs citations

77
times ranked

3259
citing authors

#	ARTICLE	IF	CITATIONS
1	Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity. <i>Microorganisms</i> , 2022, 10, 494.	1.6	1
2	The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 977.	1.1	1
3	Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients. <i>Diagnostics</i> , 2021, 11, 884.	1.3	3
4	Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	40
5	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	1.4	52
6	Detection of serum soluble HLA-G levels in patients with acute ischemic stroke: A pilot study. <i>Human Immunology</i> , 2020, 81, 156-161.	1.2	6
7	Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients. <i>Journal of Cellular Physiology</i> , 2020, 235, 5847-5855.	2.0	4
8	Increased age and male sex are independently associated with higher frequency of blood-affected cerebrospinal fluid barrier dysfunction using the albumin quotient. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 14.	2.4	38
9	Sexual dimorphism in the cerebrospinal fluid total protein content. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1885-1890.	1.4	7
10	Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2019, 16, 131.	3.1	31
11	Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients. <i>Disease Markers</i> , 2019, 2019, 1-5.	0.6	8
12	Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment. <i>Scientific Reports</i> , 2019, 9, 20009.	1.6	66
13	Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. <i>Neurological Sciences</i> , 2019, 40, 603-609.	0.9	12
14	Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients. <i>Frontiers in Neurology</i> , 2018, 9, 1080.	1.1	17
15	Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara. <i>Neuroepidemiology</i> , 2018, 51, 158-165.	1.1	10
16	Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 439-441.	0.9	53
17	Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2017, 377, 133-136.	0.3	8
18	Cerebrospinal fluid analysis and the determination of oligoclonal bands. <i>Neurological Sciences</i> , 2017, 38, 217-224.	0.9	30

#	ARTICLE	IF	CITATIONS
19	A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis. <i>Journal of Neurology & Neurophysiology</i> , 2017, 08, .	0.1	1
20	Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. <i>Disease Markers</i> , 2016, 2016, 1-7.	0.6	6
21	Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology. <i>Disease Markers</i> , 2016, 2016, 1-2.	0.6	8
22	Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	31
23	Comparison of Antibodies with Amylase Activity from Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0154688.	1.1	24
24	Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis. <i>Journal of Translational Medicine</i> , 2016, 14, 216.	1.8	8
25	Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 81, 356-363.	1.2	47
26	Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 245-249.	1.4	11
27	Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. <i>Disease Markers</i> , 2015, 2015, 1-5.	0.6	13
28	TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1121-1130.	1.4	23
29	Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e93001.	1.1	30
30	Comparison of Antibodies Hydrolyzing Myelin Basic Protein from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e107807.	1.1	37
31	Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. <i>Journal of Neuroinflammation</i> , 2014, 11, 188.	3.1	33
32	Significant Low Prevalence of Antibodies Reacting with Simian Virus 40 Mimotopes in Serum Samples from Patients Affected by Inflammatory Neurologic Diseases, Including Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e110923.	1.1	11
33	Serum ferroxidase activity in patients with multiple sclerosis: a pilot study. <i>In Vivo</i> , 2014, 28, 1197-200.	0.6	10
34	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 944-955.	2.1	29
35	Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker. <i>Neurological Sciences</i> , 2013, 34, 769-771.	0.9	7
36	Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. <i>Molecular and Cellular Biochemistry</i> , 2013, 381, 243-255.	1.4	73

#	ARTICLE	IF	CITATIONS
37	Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms. <i>Journal of Biochemistry</i> , 2012, 151, 493-499.	0.9	19
38	Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. <i>Human Immunology</i> , 2012, 73, 1140-1146.	1.2	51
39	Intrathecal levels of vitamin D and IgG in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012, 125, e28-e31.	1.0	23
40	Emerging topics and new perspectives on HLA-G. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 433-451.	2.4	69
41	Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 517-521.	0.9	21
42	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	0.6	86
43	Altered miRNA expression in T regulatory cells in course of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 226, 165-171.	1.1	188
44	<i>Chlamydomydia pneumoniae</i> Infection and Its Role in Neurological Disorders. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2010, 2010, 1-18.	0.6	48
45	Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 883-887.	1.4	33
46	Timing of Serum Active MMP-9 and MMP-2 Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage. <i>Acta Neurochirurgica Supplementum</i> , 2010, 106, 137-140.	0.5	42
47	Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage. <i>Acta Neurochirurgica Supplementum</i> , 2010, 106, 141-145.	0.5	6
48	Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 547-554.	1.4	31
49	<i>Chlamydia pneumoniae</i> specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. <i>Journal of NeuroVirology</i> , 2009, 15, 425-433.	1.0	19
50	Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis. <i>Human Immunology</i> , 2009, 70, 981-987.	1.2	17
51	25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1280-1285.	1.4	79
52	Neuroimmune Interactions That Operate In The Development And Progression Of Inflammatory Demyelinating Diseases: Lessons From Pathogenesis Of Multiple Sclerosis. , 2009, , 291-318.		0
53	Inhibition of multiple sclerosis associated retrovirus as biomarker of interferon therapy. <i>Journal of NeuroVirology</i> , 2008, 14, 73-77.	1.0	55
54	<i>Chlamydomydia pneumoniae</i> DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis. <i>Neuroscience Research</i> , 2008, 62, 58-61.	1.0	25

#	ARTICLE	IF	CITATIONS
55	CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 446-454.	1.4	38
56	Molecular detection of <i>Parachlamydia</i> -like organisms in cerebrospinal fluid of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 564-566.	1.4	12
57	Under the Microscope: Focus on <i>Chlamydia pneumoniae</i> Infection and Multiple Sclerosis. <i>Current Neurovascular Research</i> , 2008, 5, 60-70.	0.4	34
58	Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies. <i>Multiple Sclerosis Journal</i> , 2007, 13, 561-562.	1.4	2
59	Erratum. <i>Multiple Sclerosis Journal</i> , 2007, 13, 691-692.	1.4	2
60	Influence of Different Strategies of Volume Replacement on the Activity of Matrix Metalloproteinases. <i>Anesthesiology</i> , 2007, 106, 85-91.	1.3	34
61	Effects of anticoagulants on the activity of gelatinases. <i>Clinical Biochemistry</i> , 2007, 40, 1272-1276.	0.8	26
62	Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting Multiple Sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 192, 219-225.	1.1	35
63	Multiple Sclerosis and HERV-W/MSRV: A Multicentric Study. <i>International Journal of Biomedical Science</i> , 2007, 3, 292-7.	0.5	17
64	Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 294-301.	1.4	127
65	Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 2-12.	1.4	51
66	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. <i>Journal of the Neurological Sciences</i> , 2005, 237, 5-11.	0.3	13
67	Cerebrospinal fluid molecular demonstration of <i>Chlamydia pneumoniae</i> DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 360-369.	1.4	47
68	Beneficial effect of interferon- β 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. <i>Journal of Neuroimmunology</i> , 2004, 148, 206-211.	1.1	23
69	Intrathecal production of <i>Chlamydia pneumoniae</i> -specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms. <i>Journal of the Neurological Sciences</i> , 2004, 217, 181-188.	0.3	24
70	Molecular identification and antibody testing of <i>Chlamydia pneumoniae</i> in a subgroup of patients with HIV-associated dementia complex. Preliminary results. <i>Journal of Neuroimmunology</i> , 2003, 136, 172-177.	1.1	17
71	Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. <i>Journal of Neuroimmunology</i> , 2003, 142, 149-158.	1.1	79
72	Detection of Antibodies Directed against Human Herpesvirus 6 U94/REP in Sera of Patients Affected by Multiple Sclerosis. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4131-4137.	1.8	41

#	ARTICLE	IF	CITATIONS
73	Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules. <i>Journal of Neuroimmunology</i> , 2002, 133, 151-159.	1.1	19
74	Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders. <i>Journal of Neuroimmunology</i> , 2001, 119, 278-286.	1.1	11
75	Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with <i>Toxoplasma gondii</i> encephalitis. <i>Journal of Neuroimmunology</i> , 2000, 108, 221-226.	1.1	20